...
首页> 外文期刊>BMC Gastroenterology >Patient characteristics, clinical manifestations, prognosis, and factors associated with gastrointestinal cytomegalovirus infection in immunocompetent patients
【24h】

Patient characteristics, clinical manifestations, prognosis, and factors associated with gastrointestinal cytomegalovirus infection in immunocompetent patients

机译:免疫活性患者患者的患者特征,临床表现,预后和与胃肠巨细胞病毒感染相关的因素

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Gastrointestinal (GI) cytomegaloviral (CMV) infection is common among patients with immunocompromised status; however, data specific to GI-CMV infection in immunocompetent patients are comparatively limited. This retrospective study included patients diagnosed with GI-CMV infection at Siriraj Hospital (Bangkok, Thailand) during 2008–2017. Baseline characteristics, presentations, comorbid conditions, endoscopic findings, treatments, and outcomes were compared between immunocompetent and immunocompromised. One hundred and seventy-three patients (56 immunocompetent, 117 immunocompromised) were included. Immunocompetent patients were significantly older than immunocompromised patients (73 vs. 48.6?years, p??0.0001). Significantly more immunocompetent patients were in the ICU at the time of diagnosis (21.0% vs. 8.6%, p?=?0.024). GI bleeding was the leading presentation in immunocompetent, while diarrhea and abdominal pain were more common in immunocompromised. Blood CMV viral load was negative in significantly more immunocompetent than immunocompromised (40.7% vs. 12.9%, p?=?0.002). Ganciclovir was the main treatment in both groups. Significantly more immunocompetent than immunocompromised did not receive any specific therapy (25.5% vs. 4.4%, p?≤?0.01). Six-month mortality was significantly higher among immunocompetent patients (39.0% vs. 22.0%, p?=?0.047). Independent predictors of death were old age and inpatient or ICU clinical setting. Treatment with antiviral agents was the only independent protective factor. GI-CMV infection was frequently observed among immunocompetent elderly patients with comorbidities or severe concomitant illnesses. GI bleeding was the most common presentation. Blood CMV viral load was not diagnostically helpful. Significantly higher mortality was observed in immunocompetent than in immunocompromised patients, but this could be due to more severe concomitant illnesses in the immunocompetent group.
机译:胃肠道(GI)巨细胞病毒(CMV)感染在免疫功能性地位的患者中是常见的;然而,免疫活性患者GI-CMV感染特异性的数据相对有限。该回顾性研究包括在2008 - 2017年在Siriraj医院(曼谷,泰国曼谷,泰国)诊断出患有Gi-CMV感染的患者。在免疫活性剂和免疫环化之间比较了基线特征,介绍,共用条件,内窥镜发现,治疗和结果。包括一百七十三名患者(56例免疫因素,117例免疫普及)。免疫活性患者比免疫组织患者显着较大(73 vs.48.6?岁,P?<?0.0001)。在诊断时明显更多免疫活性患者在ICU中(21.0%vs.8.6%,p?= 0.024)。 GI出血是免疫活性的主要介绍,而腹泻和腹痛在免疫血肿中更常见。血液CMV病毒负载在显着更高的免疫活性度下是阴性的,比免疫脯(40.7%对12.9%,p?= 0.002)。 Ganciclovir是两组的主要疗法。明显更多的免疫表现不比免疫血肿没有接受任何特异性治疗(25.5%与4.4%,p?≤≤0.01)。免疫活性患者六个月的死亡率显着高(39.0%,P?= 0.047)。死亡的独立预测因素是老年和住院患者或ICU临床环境。用抗病毒剂治疗是唯一独立的保护因子。在免疫活性剂老年患者中经常观察到GI-CMV感染或严重伴随疾病。 gi出血是最常见的演示。血液CMV病毒载荷没有诊断地帮助。在免疫活性剂中观察到显着较高的死亡率,而不是免疫因素患者,但这可能是由于免疫活性组中更严重的伴随疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号